Guggenheim Capital’s Biolase, Inc. BIOL Stock Holding History

Guggenheim Capital’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2	Closed	-$9K	–	2653
2018 Q1	$9K	Hold	2	–	–	﹤0.01%	2765
2017 Q4	$9K	Hold	2	–	–	﹤0.01%	2692
2017 Q3	$15K	Buy	2 +1	+100%	+$8.62K	﹤0.01%	2763
2017 Q2	$12K	Hold	1	–	–	﹤0.01%	2802
2017 Q1	$17K	Hold	1	–	–	﹤0.01%	2795
2016 Q4	$18K	Hold	1	–	–	﹤0.01%	2857
2016 Q3	$22K	Hold	1	–	–	﹤0.01%	2820
2016 Q2	$15K	Hold	1	–	–	﹤0.01%	2826
2016 Q1	$17K	Buy	+1	New	+$12.5K	﹤0.01%	2835
2014 Q3	–	Sell	-1	Closed	-$35K	–	3147
2014 Q2	$35K	Sell	1 -1	-50%	-$25.5K	﹤0.01%	3116
2014 Q1	$64K	Hold	2	–	–	﹤0.01%	3090
2013 Q4	$63K	Buy	2 +1	+100%	+$23.7K	﹤0.01%	3033
2013 Q3	$33K	Hold	1	–	–	﹤0.01%	2982
2013 Q2	$54K	Buy	+1	New	+$55.9K	﹤0.01%	2900

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Princeton Capital Management Red Bank, New Jersey $367M AUM 45.24% 1-Year Est. Return

Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Guggenheim Capital's BIOL Position: Q2 2018 in Review

Guggenheim Capital sold out of Biolase, Inc. (BIOL) in Q2 2018, closing a stake of 2 shares — an estimated $9K sold.

Guggenheim Capital first reported a position in BIOL in Q2 2013 and held it in 14 quarters. The position peaked at $64K in Q1 2014. 18 funds tracked by Wall St. Rank hold BIOL as of Q2 2018.

Guggenheim Capital reported no remaining Biolase, Inc. position as of Q2 2018 after selling out during the quarter.
Guggenheim Capital sold 2 Biolase, Inc. shares in Q2 2018, an estimated $9K.
Guggenheim Capital first reported a position in Biolase, Inc. in Q2 2013 and held it in 14 quarters.
Guggenheim Capital's Biolase, Inc. position peaked at $64K in Q1 2014.
18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.